• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Exscientia Plc

    2/4/22 4:26:08 PM ET
    $EXAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EXAI alert in real time by email
    SC 13G 1 us30223g1022_020422.txt dXMzMDIyM2cxMDIyXzAyMDQyMi50eHQKClNFQ1VSSVRJRVMgQU5EIEVYQ0hBTkdFIENPTU1JU1NJ T04KCldhc2hpbmd0b24sIEQuQy4gMjA1NDkKClNDSEVEVUxFIDEzRwoKVW5kZXIgdGhlIFNlY3Vy aXRpZXMgRXhjaGFuZ2UgQWN0IG9mIDE5MzQKCihBbWVuZG1lbnQgTm86ICApCgpFeHNjaWVudGlh IHBsYwotLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLQooTmFtZSBvZiBJc3N1ZXIpCgogQ29tbW9uIFN0b2NrCi0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tCihUaXRsZSBvZiBDbGFzcyBvZiBT ZWN1cml0aWVzKQoKMzAyMjNHMTAyCi0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLS0tLS0tLS0tLS0tLS0tLS0tCihDVVNJUCBOdW1iZXIpCgpEZWNlbWJlciAzMSwgMjAyMQot LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLQoo RGF0ZSBvZiBFdmVudCBXaGljaCBSZXF1aXJlcyBGaWxpbmcgb2YgdGhpcyBTdGF0ZW1lbnQpCgpD aGVjayB0aGUgYXBwcm9wcmlhdGUgYm94IHRvIGRlc2lnbmF0ZSB0aGUgcnVsZSBwdXJzdWFudCB0 bwp3aGljaCB0aGlzIFNjaGVkdWxlIGlzIGZpbGVkOgoKW1hdIFJ1bGUgMTNkLTEoYikKWyBdIFJ1 bGUgMTNkLTEoYykKWyBdIFJ1bGUgMTNkLTEoZCkKCgoqVGhlIHJlbWFpbmRlciBvZiB0aGlzIGNv dmVyIHBhZ2Ugc2hhbGwgYmUgZmlsbGVkIG91dApmb3IgYSByZXBvcnRpbmcgcGVyc29uJ3MgaW5p dGlhbCBmaWxpbmcgb24gdGhpcyBmb3JtIHdpdGgKcmVzcGVjdCB0byB0aGUgc3ViamVjdCBjbGFz cyBvZiBzZWN1cml0aWVzLCBhbmQgZm9yIGFueQpzdWJzZXF1ZW50IGFtZW5kbWVudCBjb250YWlu aW5nIGluZm9ybWF0aW9uIHdoaWNoCndvdWxkIGFsdGVyIHRoZSBkaXNjbG9zdXJlcyBwcm92aWRl ZCBpbiBhIHByaW9yIGNvdmVyIHBhZ2UuCgpUaGUgaW5mb3JtYXRpb24gcmVxdWlyZWQgaW4gdGhl IHJlbWFpbmRlciBvZiB0aGlzIGNvdmVyCnBhZ2Ugc2hhbGwgbm90IGJlIGRlZW1lZCB0byBiZSAi ZmlsZWQiIGZvciB0aGUgcHVycG9zZQpvZiBTZWN0aW9uIDE4IG9mIHRoZSBTZWN1cml0aWVzIEV4 Y2hhbmdlIEFjdCBvZiAxOTM0CigiQWN0Iikgb3Igb3RoZXJ3aXNlIHN1YmplY3QgdG8gdGhlIGxp YWJpbGl0aWVzIG9mIHRoYXQKc2VjdGlvbiBvZiB0aGUgQWN0IGJ1dCBzaGFsbCBiZSBzdWJqZWN0 IHRvIGFsbCBvdGhlcgpwcm92aXNpb25zIG9mIHRoZSBBY3QgKGhvd2V2ZXIsIHNlZSB0aGUgTm90 ZXMpLgoKCgoKCkNVU0lQIE5vLiAgIDMwMjIzRzEwMgoKKDEpTmFtZXMgb2YgcmVwb3J0aW5nIHBl cnNvbnMuIEJsYWNrUm9jaywgSW5jLgoKCigyKSBDaGVjayB0aGUgYXBwcm9wcmlhdGUgYm94IGlm IGEgbWVtYmVyIG9mIGEgZ3JvdXAKKGEpIFsgIF0KKGIpIFtYXQoKCigzKSBTRUMgdXNlIG9ubHkK Cig0KSBDaXRpemVuc2hpcCBvciBwbGFjZSBvZiBvcmdhbml6YXRpb24KCkRlbGF3YXJlCgpOdW1i ZXIgb2Ygc2hhcmVzIGJlbmVmaWNpYWxseSBvd25lZCBieSBlYWNoIHJlcG9ydGluZyBwZXJzb24g d2l0aDoKCig1KSBTb2xlIHZvdGluZyBwb3dlcgoKIDY0NzU4MjMKCig2KSBTaGFyZWQgdm90aW5n IHBvd2VyCgogMAoKKDcpIFNvbGUgZGlzcG9zaXRpdmUgcG93ZXIKCiA2NTI0NTAwCgooOCkgU2hh cmVkIGRpc3Bvc2l0aXZlIHBvd2VyCgogMAoKKDkpIEFnZ3JlZ2F0ZSBhbW91bnQgYmVuZWZpY2lh bGx5IG93bmVkIGJ5IGVhY2ggcmVwb3J0aW5nIHBlcnNvbgoKIDY1MjQ1MDAKCigxMCkgQ2hlY2sg aWYgdGhlIGFnZ3JlZ2F0ZSBhbW91bnQgaW4gUm93ICg5KSBleGNsdWRlcyBjZXJ0YWluIHNoYXJl cwoKKDExKSBQZXJjZW50IG9mIGNsYXNzIHJlcHJlc2VudGVkIGJ5IGFtb3VudCBpbiBSb3cgOQoK IDUuNSUKCigxMikgVHlwZSBvZiByZXBvcnRpbmcgcGVyc29uCgpIQwoKCgoKCkl0ZW0gMS4KCkl0 ZW0gMShhKSBOYW1lIG9mIGlzc3VlcjoKLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0KCkV4c2NpZW50aWEgcGxjCgpJ dGVtIDEoYikgQWRkcmVzcyBvZiBpc3N1ZXIncyBwcmluY2lwYWwgZXhlY3V0aXZlIG9mZmljZXM6 Ci0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLS0tLS0tLS0tLS0tCgpUaGUgU2Nocm9kaW5nZXIgQnVpbGRpbmcsIE94Zm9yZCBTY2llbmNl IFBhcmsKT3hmb3JkIE9YNCA0R0UgVW5pdGVkIEtpbmdkb20KCgpJdGVtIDIuCgoKMihhKSBOYW1l IG9mIHBlcnNvbiBmaWxpbmc6Ci0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0KQmxhY2tSb2NrLCBJbmMuCgoKMihiKSBB ZGRyZXNzIG9yIHByaW5jaXBhbCBidXNpbmVzcyBvZmZpY2Ugb3IsIGlmIG5vbmUsIHJlc2lkZW5j ZToKLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLS0tLS0tLS0tLS0tLS0KQmxhY2tSb2NrLCBJbmMuCjU1IEVhc3QgNTJuZCBTdHJlZXQKTmV3 IFlvcmssIE5ZIDEwMDU1CgoKMihjKSBDaXRpemVuc2hpcDoKLS0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0KIFNlZSBJdGVt IDQgb2YgQ292ZXIgUGFnZQoKCjIoZCkgVGl0bGUgb2YgY2xhc3Mgb2Ygc2VjdXJpdGllczoKLS0t LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0t LS0tLS0tLQoKIENvbW1vbiBTdG9jawoKMihlKSBDVVNJUCBOby46ClNlZSBDb3ZlciBQYWdlCgoK CgoKCkl0ZW0gMy4KCklmIHRoaXMgc3RhdGVtZW50IGlzIGZpbGVkIHB1cnN1YW50IHRvIFJ1bGVz IDEzZC0xKGIpLCBvciAxM2QtMihiKSBvciAoYyksCmNoZWNrIHdoZXRoZXIgdGhlIHBlcnNvbiBm aWxpbmcgaXMgYToKWyBdIEJyb2tlciBvciBkZWFsZXIgcmVnaXN0ZXJlZCB1bmRlciBTZWN0aW9u IDE1IG9mIHRoZSBBY3Q7ClsgXSBCYW5rIGFzIGRlZmluZWQgaW4gU2VjdGlvbiAzKGEpKDYpIG9m IHRoZSBBY3Q7ClsgXSBJbnN1cmFuY2UgY29tcGFueSBhcyBkZWZpbmVkIGluIFNlY3Rpb24gMyhh KSgxOSkgb2YgdGhlIEFjdDsKWyBdIEludmVzdG1lbnQgY29tcGFueSByZWdpc3RlcmVkIHVuZGVy IFNlY3Rpb24gOCBvZiB0aGUKSW52ZXN0bWVudCBDb21wYW55IEFjdCBvZiAxOTQwOwpbIF0gQW4g aW52ZXN0bWVudCBhZHZpc2VyIGluIGFjY29yZGFuY2Ugd2l0aCBSdWxlIDEzZC0xKGIpKDEpKGlp KShFKTsKWyBdIEFuIGVtcGxveWVlIGJlbmVmaXQgcGxhbiBvciBlbmRvd21lbnQgZnVuZCBpbiBh Y2NvcmRhbmNlIHdpdGgKICAgICAgICAgICAgUnVsZSAxM2QtMShiKSgxKShpaSkoRik7CltYXSBB IHBhcmVudCBob2xkaW5nIGNvbXBhbnkgb3IgY29udHJvbCBwZXJzb24gaW4gYWNjb3JkYW5jZSB3 aXRoCiAgICAgICAgICAgIFJ1bGUgMTNkLTEoYikoMSkoaWkpKEcpOwpbIF0gQSBzYXZpbmdzIGFz c29jaWF0aW9ucyBhcyBkZWZpbmVkIGluIFNlY3Rpb24gMyhiKSBvZiB0aGUgRmVkZXJhbAogICAg ICAgICAgICBEZXBvc2l0IEluc3VyYW5jZSBBY3QgKDEyIFUuUy5DLiAxODEzKTsKWyBdIEEgY2h1 cmNoIHBsYW4gdGhhdCBpcyBleGNsdWRlZCBmcm9tIHRoZSBkZWZpbml0aW9uIG9mIGFuCiAgICAg ICAgICAgIGludmVzdG1lbnQgY29tcGFueSB1bmRlciBzZWN0aW9uIDMoYykoMTQpIG9mIHRoZSBJ bnZlc3RtZW50IENvbXBhbnkKICAgICAgICAgICAgQWN0IG9mIDE5NDA7ClsgXSBBIG5vbi1VLlMu IGluc3RpdHV0aW9uIGluIGFjY29yZGFuY2Ugd2l0aAogICAgICAgICAgICBSdWxlIDI0MC4xM2Qt MShiKSgxKShpaSkoSik7ClsgXSBHcm91cCwgaW4gYWNjb3JkYW5jZSB3aXRoIFJ1bGUgMjQwLjEz ZC0xKGIpKDEpKGlpKShLKS4gSWYgZmlsaW5nCiAgICAgICAgICAgIGFzIGEgbm9uLVUuUy4gaW5z dGl0dXRpb24gaW4gYWNjb3JkYW5jZSB3aXRoCiAgICAgICAgICAgIFJ1bGUgMjQwLjEzZC0xKGIp KDEpKGlpKShKKSwgcGxlYXNlIHNwZWNpZnkgdGhlIHR5cGUgb2YKICAgICAgICAgICAgaW5zdGl0 dXRpb246CgoKSXRlbSA0LiBPd25lcnNoaXAKClByb3ZpZGUgdGhlIGZvbGxvd2luZyBpbmZvcm1h dGlvbiByZWdhcmRpbmcgdGhlIGFnZ3JlZ2F0ZSBudW1iZXIKYW5kIHBlcmNlbnRhZ2Ugb2YgdGhl IGNsYXNzIG9mIHNlY3VyaXRpZXMgb2YgdGhlIGlzc3VlciBpZGVudGlmaWVkIGluIEl0ZW0gMS4K CgpBbW91bnQgYmVuZWZpY2lhbGx5IG93bmVkOgoKICA2NTI0NTAwCgpQZXJjZW50IG9mIGNsYXNz Cgo1LjUlCgpOdW1iZXIgb2Ygc2hhcmVzIGFzIHRvIHdoaWNoIHN1Y2ggcGVyc29uIGhhczoKClNv bGUgcG93ZXIgdG8gdm90ZSBvciB0byBkaXJlY3QgdGhlIHZvdGUKCiAgNjQ3NTgyMwoKU2hhcmVk IHBvd2VyIHRvIHZvdGUgb3IgdG8gZGlyZWN0IHRoZSB2b3RlCgogIDAKClNvbGUgcG93ZXIgdG8g ZGlzcG9zZSBvciB0byBkaXJlY3QgdGhlIGRpc3Bvc2l0aW9uIG9mCgogIDY1MjQ1MDAKClNoYXJl ZCBwb3dlciB0byBkaXNwb3NlIG9yIHRvIGRpcmVjdCB0aGUgZGlzcG9zaXRpb24gb2YKCiAgMAoK CgoKCgoKCgpJdGVtIDUuCgpPd25lcnNoaXAgb2YgNSBQZXJjZW50IG9yIExlc3Mgb2YgYSBDbGFz cy4gSWYgdGhpcyBzdGF0ZW1lbnQgaXMgYmVpbmcKZmlsZWQgdG8gcmVwb3J0IHRoZSBmYWN0IHRo YXQgYXMgb2YgdGhlIGRhdGUgaGVyZW9mIHRoZSByZXBvcnRpbmcgcGVyc29uCmhhcyBjZWFzZWQg dG8gYmUgdGhlIGJlbmVmaWNpYWwgb3duZXIgb2YgbW9yZSB0aGFuIDUgcGVyY2VudCBvZiB0aGUK Y2xhc3Mgb2Ygc2VjdXJpdGllcywgY2hlY2sgdGhlIGZvbGxvd2luZyBbICBdLgoKCkl0ZW0gNi4g T3duZXJzaGlwIG9mIE1vcmUgdGhhbiA1IFBlcmNlbnQgb24gQmVoYWxmIG9mIEFub3RoZXIgUGVy c29uCgogIElmIGFueSBvdGhlciBwZXJzb24gaXMga25vd24gdG8gaGF2ZSB0aGUgcmlnaHQgdG8g cmVjZWl2ZSBvciB0aGUgcG93ZXIKICB0byBkaXJlY3QgdGhlIHJlY2VpcHQgb2YgZGl2aWRlbmRz IGZyb20sIG9yIHRoZSBwcm9jZWVkcyBmcm9tIHRoZSBzYWxlCiAgb2YsIHN1Y2ggc2VjdXJpdGll cywgYSBzdGF0ZW1lbnQgdG8gdGhhdCBlZmZlY3Qgc2hvdWxkIGJlIGluY2x1ZGVkIGluCiAgcmVz cG9uc2UgdG8gdGhpcyBpdGVtIGFuZCwgaWYgc3VjaCBpbnRlcmVzdCByZWxhdGVzIHRvIG1vcmUg dGhhbiA1IHBlcmNlbnQKICBvZiB0aGUgY2xhc3MsIHN1Y2ggcGVyc29uIHNob3VsZCBiZSBpZGVu dGlmaWVkLiBBIGxpc3Rpbmcgb2YgdGhlCiAgc2hhcmVob2xkZXJzIG9mIGFuIGludmVzdG1lbnQg Y29tcGFueSByZWdpc3RlcmVkIHVuZGVyIHRoZSBJbnZlc3RtZW50CiAgQ29tcGFueSBBY3Qgb2Yg MTk0MCBvciB0aGUgYmVuZWZpY2lhcmllcyBvZiBlbXBsb3llZSBiZW5lZml0IHBsYW4sCiAgcGVu c2lvbiBmdW5kIG9yIGVuZG93bWVudCBmdW5kIGlzIG5vdCByZXF1aXJlZC4KCiAgVmFyaW91cyBw ZXJzb25zIGhhdmUgdGhlIHJpZ2h0IHRvIHJlY2VpdmUgb3IgdGhlIHBvd2VyIHRvIGRpcmVjdAog ICB0aGUgcmVjZWlwdCBvZiBkaXZpZGVuZHMgZnJvbSwgb3IgdGhlIHByb2NlZWRzIGZyb20gdGhl IHNhbGUgb2YKICAgdGhlIGNvbW1vbiBzdG9jayBvZgogICBFeHNjaWVudGlhIHBsYy4KICAgTm8g b25lIHBlcnNvbidzIGludGVyZXN0IGluIHRoZSBjb21tb24gc3RvY2sgb2YKICAgRXhzY2llbnRp YSBwbGMKICAgaXMgbW9yZSB0aGFuIGZpdmUgcGVyY2VudCBvZiB0aGUgdG90YWwgb3V0c3RhbmRp bmcgY29tbW9uIHNoYXJlcy4KCkl0ZW0gNy4gSWRlbnRpZmljYXRpb24gYW5kIENsYXNzaWZpY2F0 aW9uIG9mIHRoZSBTdWJzaWRpYXJ5IFdoaWNoCkFjcXVpcmVkIHRoZSBTZWN1cml0eSBCZWluZyBS ZXBvcnRlZCBvbiBieSB0aGUgUGFyZW50IEhvbGRpbmcKQ29tcGFueSBvciBDb250cm9sIFBlcnNv bi4KCgpTZWUgRXhoaWJpdCBBCgoKSXRlbSA4LiBJZGVudGlmaWNhdGlvbiBhbmQgQ2xhc3NpZmlj YXRpb24gb2YgTWVtYmVycyBvZiB0aGUgR3JvdXAKCgpJZiBhIGdyb3VwIGhhcyBmaWxlZCB0aGlz IHNjaGVkdWxlIHB1cnN1YW50IHRvIFJ1bGUgMTNkLTEoYikoaWkpKEopLApzbyBpbmRpY2F0ZSB1 bmRlciBJdGVtIDMoaikgYW5kIGF0dGFjaCBhbiBleGhpYml0IHN0YXRpbmcgdGhlIGlkZW50aXR5 CmFuZCBJdGVtIDMgY2xhc3NpZmljYXRpb24gb2YgZWFjaCBtZW1iZXIgb2YgdGhlIGdyb3VwLiBJ ZiBhIGdyb3VwCmhhcyBmaWxlZCB0aGlzIHNjaGVkdWxlIHB1cnN1YW50IHRvIFJ1bGUgMTNkLTEo Yykgb3IgUnVsZSAxM2QtMShkKSwKYXR0YWNoIGFuIGV4aGliaXQgc3RhdGluZyB0aGUgaWRlbnRp dHkgb2YgZWFjaCBtZW1iZXIgb2YgdGhlIGdyb3VwLgoKCkl0ZW0gOS4gTm90aWNlIG9mIERpc3Nv bHV0aW9uIG9mIEdyb3VwCgpOb3RpY2Ugb2YgZGlzc29sdXRpb24gb2YgYSBncm91cCBtYXkgYmUg ZnVybmlzaGVkIGFzIGFuIGV4aGliaXQKc3RhdGluZyB0aGUgZGF0ZSBvZiB0aGUgZGlzc29sdXRp b24gYW5kIHRoYXQgYWxsIGZ1cnRoZXIgZmlsaW5ncyB3aXRoCnJlc3BlY3QgdG8gdHJhbnNhY3Rp b25zIGluIHRoZSBzZWN1cml0eSByZXBvcnRlZCBvbiB3aWxsIGJlIGZpbGVkLAppZiByZXF1aXJl ZCwgYnkgbWVtYmVycyBvZiB0aGUgZ3JvdXAsIGluIHRoZWlyIGluZGl2aWR1YWwgY2FwYWNpdHku CgpTZWUgSXRlbSA1LgoKSXRlbSAxMC4gQ2VydGlmaWNhdGlvbnMKQnkgc2lnbmluZyBiZWxvdyBJ IGNlcnRpZnkgdGhhdCwgdG8gdGhlIGJlc3Qgb2YgbXkga25vd2xlZGdlIGFuZApiZWxpZWYsIHRo ZSBzZWN1cml0aWVzIHJlZmVycmVkIHRvIGFib3ZlIHdlcmUgYWNxdWlyZWQgYW5kIGFyZQpoZWxk IGluIHRoZSBvcmRpbmFyeSBjb3Vyc2Ugb2YgYnVzaW5lc3MgYW5kIHdlcmUgbm90IGFjcXVpcmVk CmFuZCBhcmUgbm90IGhlbGQgZm9yIHRoZSBwdXJwb3NlIG9mIG9yIHdpdGggdGhlIGVmZmVjdCBv ZiBjaGFuZ2luZwpvciBpbmZsdWVuY2luZyB0aGUgY29udHJvbCBvZiB0aGUgaXNzdWVyIG9mIHRo ZSBzZWN1cml0aWVzIGFuZCB3ZXJlCm5vdCBhY3F1aXJlZCBhbmQgYXJlIG5vdCBoZWxkIGluIGNv bm5lY3Rpb24gd2l0aCBvciBhcyBhIHBhcnRpY2lwYW50CmluIGFueSB0cmFuc2FjdGlvbiBoYXZp bmcgdGhhdCBwdXJwb3NlIG9yIGVmZmVjdC4KClNpZ25hdHVyZS4KCkFmdGVyIHJlYXNvbmFibGUg aW5xdWlyeSBhbmQgdG8gdGhlIGJlc3Qgb2YgbXkga25vd2xlZGdlIGFuZApiZWxpZWYsIEkgY2Vy dGlmeSB0aGF0IHRoZSBpbmZvcm1hdGlvbiBzZXQgZm9ydGggaW4gdGhpcyBzdGF0ZW1lbnQKaXMg dHJ1ZSwgY29tcGxldGUgYW5kIGNvcnJlY3QuCgoKRGF0ZWQ6IEZlYnJ1YXJ5IDQsIDIwMjIKQmxh Y2tSb2NrLCBJbmMuCgoKU2lnbmF0dXJlOiAgU3BlbmNlciBGbGVtaW5nCgoKCi0tLS0tLS0tLS0t LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0KCk5hbWUvVGl0bGUgQXR0b3JuZXktSW4t RmFjdAoKClRoZSBvcmlnaW5hbCBzdGF0ZW1lbnQgc2hhbGwgYmUgc2lnbmVkIGJ5IGVhY2ggcGVy c29uIG9uIHdob3NlCmJlaGFsZiB0aGUgc3RhdGVtZW50IGlzIGZpbGVkIG9yIGhpcyBhdXRob3Jp emVkIHJlcHJlc2VudGF0aXZlLgpJZiB0aGUgc3RhdGVtZW50IGlzIHNpZ25lZCBvbiBiZWhhbGYg b2YgYSBwZXJzb24gYnkgaGlzIGF1dGhvcml6ZWQKcmVwcmVzZW50YXRpdmUgb3RoZXIgdGhhbiBh biBleGVjdXRpdmUgb2ZmaWNlciBvciBnZW5lcmFsIHBhcnRuZXIKb2YgdGhlIGZpbGluZyBwZXJz b24sIGV2aWRlbmNlIG9mIHRoZSByZXByZXNlbnRhdGl2ZSdzIGF1dGhvcml0eSB0bwpzaWduIG9u IGJlaGFsZiBvZiBzdWNoIHBlcnNvbiBzaGFsbCBiZSBmaWxlZCB3aXRoIHRoZSBzdGF0ZW1lbnQs CnByb3ZpZGVkLCBob3dldmVyLCB0aGF0IGEgcG93ZXIgb2YgYXR0b3JuZXkgZm9yIHRoaXMgcHVy cG9zZQp3aGljaCBpcyBhbHJlYWR5IG9uIGZpbGUgd2l0aCB0aGUgQ29tbWlzc2lvbiBtYXkgYmUg aW5jb3Jwb3JhdGVkCmJ5IHJlZmVyZW5jZS4gVGhlIG5hbWUgYW5kIGFueSB0aXRsZSBvZiBlYWNo IHBlcnNvbiB3aG8Kc2lnbnMgdGhlIHN0YXRlbWVudCBzaGFsbCBiZSB0eXBlZCBvciBwcmludGVk IGJlbmVhdGggaGlzIHNpZ25hdHVyZS4KCgoKQXR0ZW50aW9uOiBJbnRlbnRpb25hbCBtaXNzdGF0 ZW1lbnRzIG9yIG9taXNzaW9ucyBvZiBmYWN0IGNvbnN0aXR1dGUKRmVkZXJhbCBjcmltaW5hbCB2 aW9sYXRpb25zIChzZWUgMTggVS5TLkMuIDEwMDEpLgoKCkV4aGliaXQgQQoKCgpTdWJzaWRpYXJ5 CgoKQmxhY2tSb2NrIChMdXhlbWJvdXJnKSBTLkEuCkJsYWNrUm9jayAoTmV0aGVybGFuZHMpIEIu Vi4KQmxhY2tSb2NrIEFkdmlzb3JzIChVSykgTGltaXRlZApCbGFja1JvY2sgQWR2aXNvcnMsIExM QwpCbGFja1JvY2sgSW5zdGl0dXRpb25hbCBUcnVzdCBDb21wYW55LCBOYXRpb25hbCBBc3NvY2lh dGlvbgpCbGFja1JvY2sgSW52ZXN0bWVudCBNYW5hZ2VtZW50IChBdXN0cmFsaWEpIExpbWl0ZWQK QmxhY2tSb2NrIEludmVzdG1lbnQgTWFuYWdlbWVudCAoVUspIExpbWl0ZWQKCgoKCipFbnRpdHkg YmVuZWZpY2lhbGx5IG93bnMgNSUgb3IgZ3JlYXRlciBvZiB0aGUgb3V0c3RhbmRpbmcKc2hhcmVz IG9mIHRoZSBzZWN1cml0eSBjbGFzcyBiZWluZyByZXBvcnRlZCBvbiB0aGlzClNjaGVkdWxlIDEz Ry4KRXhoaWJpdCBCCgoKUE9XRVIgT0YgQVRUT1JORVkKClRoZSB1bmRlcnNpZ25lZCwgQkxBQ0tS T0NLLCBJTkMuLCBhIGNvcnBvcmF0aW9uIGR1bHkgb3JnYW5pemVkCnVuZGVyIHRoZSBsYXdzIG9m IHRoZSBTdGF0ZSBvZiBEZWxhd2FyZSwgVW5pdGVkIFN0YXRlcyAodGhlCiJDb21wYW55IiksIGRv ZXMgaGVyZWJ5IG1ha2UsIGNvbnN0aXR1dGUgYW5kIGFwcG9pbnQgZWFjaCBvZgpDaHJpc3RvcGhl ciBNZWFkZSwgRGFuaWVsIFdhbHRjaGVyLCBVbmEgTmVhcnksIFJpY2hhcmQgQ3VuZGlmZiwKQ2hh cmxlcyBQYXJrLCBFbmRhIE1jTWFob24sIEFybGVuZSBLbGVpbiwgQ29uIFR6YXR6YWtpcywgS2Fy ZW4gQ2xhcmssCkRhdmlkIE1hcnlsZXMsIERhbmllbCBSb25uZW4sIEpvaG4gU3RlbGxleSwgRGFu aWVsIFJpZW1lciwKRWxpemFiZXRoIEtvZ3V0LCBNYXVyZWVuIEdsZWVzb24sIERhbmllbCBLYWxp c2ggYW5kIFNwZW5jZXIgRmxlbWluZyBhY3RpbmcKc2V2ZXJhbGx5LCBhcyBpdHMgdHJ1ZSBhbmQg bGF3ZnVsIGF0dG9ybmV5cy1pbi1mYWN0LCBmb3IgdGhlIHB1cnBvc2Ugb2YsIGZyb20KdGltZSB0 byB0aW1lLCBleGVjdXRpbmcgaW4gaXRzIG5hbWUgYW5kIG9uIGl0cyBiZWhhbGYsIHdoZXRoZXIg dGhlIENvbXBhbnkKaW5kaXZpZHVhbGx5IG9yIGFzIHJlcHJlc2VudGF0aXZlIG9mIG90aGVycywg YW55IGFuZCBhbGwgZG9jdW1lbnRzLCBpcyBhY3RpbmcKY2VydGlmaWNhdGVzLCBpbnN0cnVtZW50 cywgc3RhdGVtZW50cywgb3RoZXIgZmlsaW5ncyBhbmQgYW1lbmRtZW50cyB0byB0aGUKZm9yZWdv aW5nIChjb2xsZWN0aXZlbHksICJkb2N1bWVudHMiKSBkZXRlcm1pbmVkIGJ5IHN1Y2ggcGVyc29u IHRvCmJlIG5lY2Vzc2FyeSBvciBhcHByb3ByaWF0ZSB0byBjb21wbHkgd2l0aCBvd25lcnNoaXAg b3IgY29udHJvbC1wZXJzb24KcmVwb3J0aW5nIHJlcXVpcmVtZW50cyBpbXBvc2VkIGJ5IGFueSBV bml0ZWQgU3RhdGVzIG9yIG5vbi1Vbml0ZWQgU3RhdGVzCmdvdmVybm1lbnRhbCBvciByZWd1bGF0 b3J5IGF1dGhvcml0eSwgSW5jbHVkaW5nIHdpdGhvdXQgbGltaXRhdGlvbgpGb3JtcyAzLCA0LCA1 LCAxM0QsIDEzRiwgMTNHIGFuZCAxM0ggYW5kIGFueSBhbWVuZG1lbnRzIHRvIGFueSBvZiB0aGUK Rm9yZWdvaW5nIGFzIG1heSBiZSByZXF1aXJlZCB0byBiZSBmaWxlZCB3aXRoIHRoZSBTZWN1cml0 aWVzIGFuZApFeGNoYW5nZSBDb21taXNzaW9uLCBhbmQgZGVsaXZlcmluZywgZnVybmlzaGluZyBv ciBmaWxpbmcgYW55CnN1Y2ggZG9jdW1lbnRzIHdpdGggdGhlIGFwcHJvcHJpYXRlIGdvdmVybm1l bnRhbCwgcmVndWxhdG9yeQphdXRob3JpdHkgb3Igb3RoZXIgcGVyc29uLCBhbmQgZ2l2aW5nIGFu ZCBncmFudGluZyB0byBlYWNoIHN1Y2gKYXR0b3JuZXktaW4tZmFjdCBwb3dlciBhbmQgYXV0aG9y aXR5IHRvIGFjdCBpbiB0aGUgcHJlbWlzZXMgYXMgZnVsbHkKYW5kIHRvIGFsbCBpbnRlbnRzIGFu ZCBwdXJwb3NlcyBhcyB0aGUgQ29tcGFueSBtaWdodCBvciBjb3VsZApkbyBpZiBwZXJzb25hbGx5 IHByZXNlbnQgYnkgb25lIG9mIGl0cyBhdXRob3JpemVkIHNpZ25hdG9yaWVzLApoZXJlYnkgcmF0 aWZ5aW5nIGFuZCBjb25maXJtaW5nIGFsbCB0aGF0IHNhaWQgYXR0b3JuZXktaW4tZmFjdCBzaGFs bApsYXdmdWxseSBkbyBvciBjYXVzZSB0byBiZSBkb25lIGJ5IHZpcnR1ZSBoZXJlb2YuIEFueSBz dWNoCmRldGVybWluYXRpb24gYnkgYW4gYXR0b3JuZXktaW4tZmFjdCBuYW1lZCBoZXJlaW4gc2hh bGwgYmUKY29uY2x1c2l2ZWx5IGV2aWRlbmNlZCBieSBzdWNoIHBlcnNvbidzIGV4ZWN1dGlvbiwg ZGVsaXZlcnksCmZ1cm5pc2hpbmcgb3IgZmlsaW5nIG9mIHRoZSBhcHBsaWNhYmxlIGRvY3VtZW50 LgoKVGhpcyBwb3dlciBvZiBhdHRvcm5leSBzaGFsbCBleHByZXNzbHkgcmV2b2tlIHRoZSBwb3dl ciBvZiBhdHRvcm5leQpkYXRlZCA4dGggZGF5IG9mIERlY2VtYmVyLCAyMDE1IGluIHJlc3BlY3Qg b2YgdGhlIHN1YmplY3QgbWF0dGVyIGhlcmVvZiwKc2hhbGwgYmUgdmFsaWQgZnJvbSB0aGUgZGF0 ZSBoZXJlb2YgYW5kIHNoYWxsIHJlbWFpbiBpbiBmdWxsIGZvcmNlIGFuZAplZmZlY3QgdW50aWwg ZWl0aGVyIHJldm9rZWQgaW4gd3JpdGluZyBieSB0aGUgQ29tcGFueSwgb3IsIGluIHJlc3BlY3Qg b2YKYW55IGF0dG9ybmV5LWluLWZhY3QgbmFtZWQgaGVyZWluLCB1bnRpbCBzdWNoIHBlcnNvbiBj ZWFzZXMgdG8gYmUgYW4KZW1wbG95ZWUgb2YgdGhlIENvbXBhbnkgb3Igb25lIG9mIGl0cyBhZmZp bGlhdGVzLgoKCklOIFdJVE5FU1MgV0hFUkVPRiwgdGhlIHVuZGVyc2lnbmVkIGhhcyBjYXVzZWQg dGhpcyBwb3dlciBvZgphdHRvcm5leSB0byBiZSBleGVjdXRlZCBhcyBvZiB0aGlzIDJuZCBkYXkg b2YgSmFudWFyeSwgMjAxOS4KCkJMQUNLUk9DSywgSU5DLgoKCkJ5Ol8gL3MvIERhbmllbCBXYWx0 Y2hlcgpOYW1lOiBEYW5pZWwgV2FsdGNoZXIKVGl0bGU6IERlcHV0eSBHZW5lcmFsIENvdW5zZWwK CgoKCgo=
    Get the next $EXAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXAI

    DatePrice TargetRatingAnalyst
    7/9/2024Buy
    TD Cowen
    1/5/2024$11.00 → $9.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $EXAI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Exscientia Plc

      15-12G - Exscientia plc (0001865408) (Filer)

      12/2/24 8:39:14 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Exscientia Plc

      S-8 POS - Exscientia plc (0001865408) (Filer)

      11/20/24 10:01:22 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Exscientia Plc

      S-8 POS - Exscientia plc (0001865408) (Filer)

      11/20/24 9:53:01 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

      Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discoveryRecursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (NASDAQ:RXRX) and Exscientia has been completed, wi

      11/20/24 7:00:00 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion and Exscientia Shareholders Approve the Proposed Combination

      Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) and Exscientia plc (NASDAQ:EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia.  The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET /  5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of

      11/13/24 9:08:19 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration

      Both programmes demonstrate Exscientia's ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royalties Three programmes in the partnership have now advanced through initial milestones with multiple more progressing at earlier stages Exscientia plc (NASDAQ:EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds

      10/16/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

      Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone

      8/8/24 7:39:25 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in Oncology

      — AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology drug development expertise to execute robust clinical strategy on Exscientia's internal oncology pipeline — Exscientia plc (NASDAQ:EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development. Appointed to Chief Technology Officer, John P. Overington, Ph.D.,

      6/6/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Parker Moss to Join Exscientia as EVP, Corporate Development

      Renowned technology champion to strengthen company's development of precision medicine and clinical innovation platforms Exscientia plc (NASDAQ:EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company's precision medicine, clinical and tech innovation platforms, with a particular focus on oncology. Reporting to CEO Andrew Hopkins, he will help the company's Executive Leadership Team to identify and shape new business opportuni

      10/17/23 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exscientia Plc

      SC 13G/A - Exscientia plc (0001865408) (Subject)

      11/22/24 9:11:55 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Exscientia Plc

      SC 13D/A - Exscientia plc (0001865408) (Subject)

      11/22/24 8:00:16 PM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Exscientia Plc (Amendment)

      SC 13G/A - Exscientia plc (0001865408) (Subject)

      2/12/24 11:05:40 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Financials

    Live finance-specific insights

    See more
    • Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

      Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 Exscientia plc (NASDAQ:EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. R

      7/18/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia Business Update for First Quarter 2024

      Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and streamlining operations to realise annualised savings of $40 million Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscient

      5/21/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024

      Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 (800) 358 0970 (U.K.), +1 (646) 960 0857 (International)

      5/14/24 7:00:00 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EXAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Exscientia plc

      TD Cowen initiated coverage of Exscientia plc with a rating of Buy

      7/9/24 7:31:11 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Exscientia plc downgraded by BofA Securities with a new price target

      BofA Securities downgraded Exscientia plc from Buy to Neutral and set a new price target of $9.00 from $11.00 previously

      1/5/24 7:41:29 AM ET
      $EXAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care